• 1
    Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009; 373: 1119-1132.
  • 2
    Rini BI. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res. 2010; 16: 1348-1354.
  • 3
    Currie MJ, Gunningham SP, Turner K, et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol. 2002; 198: 502-510.
  • 4
    Bullock AJ, Zhang A, O'Neill A, et al. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC) [Abstract]. J Clin Oncol. 2010; 28: 4630.
  • 5
    Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther. 2010; 9: 2641-2651.
  • 6
    Appleman LJ, Gordon MS, Samlowski W, et al. Open-label phase 1b study of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in combination with sorafenib or sunitinib in advanced renal cell carcinoma (RCC): interim results [Abstract]. Ann Oncol. 2010; 21: viii65. Abstract 505P.
  • 7
    Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009; 27: 3557-3565.
  • 8
    Bass MB, Sherman SI, Schlumberger MJ, et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab. 2010; 95: 5018-5027.
  • 9
    Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982; 38: 29-41.
  • 10
    Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 1280-1289.
  • 11
    Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 2505-2512.
  • 12
    Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
  • 13
    Jonasch E, Corn P, Pagliaro LC, et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010; 116: 57-65.
  • 14
    Mita AC, Takimoto CH, Mita M, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res. 2010; 16: 3044-3056.
  • 15
    Karlan BY, Oza AM, Richardson GE, et al. A randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012; 30: 362-371.
  • 16
    Beck J, Procopio G, Bajetta E, et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol. 2011; 22: 1812-1823.
  • 17
    Nexavar (sorafenib). Full prescribing information. Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc; 2011.
  • 18
    Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009; 10: 559-568.
  • 19
    Votrient (pazopanib). Full prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2011.
  • 20
    Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010; 28: 475-480.
  • 21
    Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 1432-1439.
  • 22
    Sosman JA, Flaherty KT, Atkins MB, et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) [Abstract]. J Clin Oncol. 2008; 26: 5011.
  • 23
    Okugawa Y, Miki C, Toiyama Y, et al. Serum soluble VCAM-1 as a valuable prognostic marker in colorectal carcinoma [Abstract]. Presented at: American Society of Clinical Oncology 2009 Gastrointestinal Cancers Symposium; January 15-17, 2009; San Francisco, CA. Abstract 319.
  • 24
    Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009; 6: 327-338.
  • 25
    Wu TC. The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res. 2007; 67: 6003-6006.
  • 26
    van der Veldt AA, Vroling L, de Haas RR, et al. Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. Int J Cancer. 2011; doi:10.1002/ijc.26456.
  • 27
    Baar J, Silverman P, Lyons J, et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res. 2009; 15: 3583-3590.
  • 28
    Denduluri N, Yang SX, Berman AW, et al. Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther. 2008; 7: 15-20.
  • 29
    Lu J-F, Rasmussen E, Karlan BY, et al. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol. 2012; 69: 1135-1144.